← Eichor
Study identifier: NCT06847399 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder

Condition: Obesity and Overweight · Binge Eating Disorder  ·  Sponsor: Johns Hopkins University

PhasePhase 2
Planned participants105
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to assess the efficacy and safety of tirzepatide in adults with obesity and binge-eating disorder, comparing tirzepatide against placebo and lisdexamfetamine dimesylate. All participants will receive guided self-help cognitive behavioral therapy.

This description comes directly from the study's public registry record.

Talk to the study team

Abigail Bisson, BS  ·  667-306-9366  ·  abisson2@jh.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Johns Hopkins UniversityBaltimore, Maryland, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06847399